Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer.

Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F. · 2011

Read Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. by Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3241564.txt.

Introduction

Antoine Lecharpentier and colleagues searched the blood of lung cancer patients for circulating tumor cells caught mid-transition, in this 2011 paper in the British Journal of Cancer. Tumor cells that shed into the blood drive metastasis and carry prognostic information. A process called epithelial-mesenchymal transition is thought to prepare them, but direct evidence in patients' circulating cells was scarce.

Using a filtration method that traps tumor cells by size, the team stained cells from six patients. All had non-small cell lung cancer that had already spread. Every patient carried tumor cells, singly and in clusters, that strongly displayed both an epithelial marker and the mesenchymal marker vimentin. Cells bearing only the mesenchymal marker were rarer, and none bore only the epithelial one. The authors present these hybrid cells as the first direct evidence of the transition in this disease.

Catalog record

CREATORLecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F.
YEAR2011
COLLECTIONPAPERS
FORMATTXT
FILE SIZE14 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3241564

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer By A Lecharpentier, P Vielh, P Perez-Moreno, D Planchard, J C Soria, F Farace Published in: British Journal of Cancer DOI: 10.1038/bjc.2011.405 ABSTRACT Background: Circulating tumour cells (CTC) have a crucial role in metastasis formation and can consistently provide information on patient prognosis. Epithelial-mesenchymal transition (EMT) is considered as an essential process in the metastatic cascade, but there is currently very few data demonstrating directly the existence of the EMT process in CTCs. Methods: CTCs were enriched by blood filtration using ISET (isolation by size of epithelial tumour cells), triply labelled with fluorescent anti-vimentin, anti-pan-keratin antibodies and SYTOX orange nuclear dye, and examined by confocal microscopy in six patients with metastatic non-small cell lung cancer (NSCLC). In parallel, CTCs were morphocytologically identified by an experienced cytopathologist. Results: Isolated or clusters of dual CTCs strongly co-expressing vimentin and keratin were evidenced in all patients (range 5–88/5 ml). CTCs expressing only vimentin were detected in three patients, but were less frequent (range 3–15/5 ml). No CTC expressing only keratin was detected. Conclusion: We showed for the first time the existence of hybrid CTCs with an epithelial/mesenchymal phenotype in patients with NSCLC. Their characterisation should provide further insight on the significance of EMT in CTCs and on the mechanism of metastasis in patients with NSCLC. Circulating tumour cells (CTCs) have an active role in the formation of metastasis and their detection can provide information on patient prognosis and treatment efficacy. Current clinical results rely exclusively on the detection and enumeration of CTCs expressing epithelial-lineage markers (i.e., the epithelial cell adhesion molecule (EpCAM and cytokeratins) in the peripheral blood (Cristofanilli et al, 2004; Cohen et al, 2008; De Bono et al, 2008; Mostert et al, 2009). Using this approach, several groups have shown an association between the CTC counts and clinical outcome of patients (Cristofanilli et al, 2004; Hayes et al, 2006; Cohen et al, 2008; De Bono et al, 2008). In most carcinomas, tumour progression implicates the loss of epithelial features and a shift towards a mesenchymal phenotype (Polyak and Weinberg, 2009; Thiery et al, 2009). During this process, referred to as the epithelial-mesenchymal transition (EMT) and considered as a pre-requisite to tumour infiltration and metastasis, epithelial carcinoma cells acquire a migratory phenotype and express mesenchymal genes (Polyak and Weinberg, 2009; Thiery et al, 2009). The phenomenon of ‘partial’ or ‘incomplete’ EMT has also been reported in which invasive and metastasising carcinoma cells may adopt a mesenchymal phenotype and express mesenchymal markers, for example, vimentin and neural cadherin while retaining epithelial charcteristics (Christiansen and Rajasekaran, 2006). However, although EMT must, by definition, have a role in the generation of at least a fraction of CTCs, there has been very few data directly demonstrating the existence of the EMT process in CTCs (Hofman et al, 2011; Hou et al, 2011). Here, we report for the first time the detection of CTCs expressing a dual epithelial and mesenchymal phenotype in the peripheral blood of patients with metastatic carcinoma. PATIENTS AND METHODS Blood sample collection The present study was approved by our institutional review board and local ethics committee. Informed and written consent was obtained from all patients. Peripheral blood samples were collected from six patients with histologically or cytologically confirmed non-small cell lung cancer (NSCLC). For each patient, 10 ml of blood was collected in EDTA tubes (Terumo, Leuven, Belgium) for CTC enumeration by isolation by size of epithelial tumour cells (ISET). Peripheral blood samples were collected from six healthy volunteers for control experiments. Immunostaining and enumeration of CTC by ISET Within 4 h after venopunction, blood samples were diluted 1 : 10 in an erythrocyte lysis buffer containing paraformaldehyde, filtered on the ISET device using filters with calibrated pores of 8 μM (Vona et al, 2000; Paterlini-Brechot and Benali, 2007). Filters were air dried and conserved at −20 °C. After thawing, filters were incubated for 20 min at 98 °C in an EDTA buffer (DAKO Target retrieval buffer, pH=9.9; Dako, Glostrup, Denmark), and treated for 5 min by triton X-100 at room temperature, in a humidity chamber for cell permeabilisation. Filters were washed with TBS for 1 min and stained with markers diluted in TBS, including Alexa Fluor 488 conjugated anti-vimentin (Santa Cruz Biotechnology, Heidelberg, Germany) and Alexa Fluor 647 conjugated anti-pan-cytokeratin (Cell Signalling, Danvers, MA, USA) antibodies and SYTOX orange (Molecular Probes, Leiden, The Netherlands) overnight at 4 °C in a humidity chamber and under obscurity. SYTOX orange is a nuclear dye for which the spectra are 545 nm for excitation and 570 nm for emission. After rinsing with TBS, filters were finally mounted using Ultramount (53001; Dako). Imaging is carried out with a confocal Zeiss LSM510 Meta microscope (Carl Zeiss France, Le Pecq, France) with a × 40 or × 63 magnification and an optical slice of 1.9 μm. Using the ImageJ software (NIH ImageJ, Version 1.42-q), a Gaussian blur (radius=0.10 μm) was applied, and contrast was slightly enhanced in every fluorescent channels of acquisitions. CTCs were selected, digitised and validated by a senior and experienced cytopathologist (PV) as cells presenting all the following criterias: (i) nuclear size equal or larger than two pores (16 μM); (ii) irregularity of the nuclear contour; (iii) presence of a visible cytoplasm; (iv) high nuclear-to-cytoplasmic ratio (greater than 0.8). A size threshold of 16 μM was chosen to exclude most normal cells. Cell lines The SKBR3 (breast cancer), MDA-MB-435S (breast cancer) and A549 (lung adenocarcinoma) cultured cell lines were used as controls for markers expression. All cell lines were cultured in 1640 RPMI medium supplemented 10% fetal calf serum and maintained in a humidified incubator in 5% CO2 at 37 °C. For control experiments, 25 cells from each cell line were precisely micro-manipulated under an inverted microscope before being spiked into blood from healthy donors. Blood samples containing spiked cell lines were then diluted using the erythrocyte lysis buffer, filtered and stained as described for patient samples. Immunohistochemical staining of tumours Immunohistochemical stainings were performed on sections of formalin-fixed paraffin-embedded samples, using cytokeratin 7 (Dako) and vimentin (Santa Cruz Biotechnology) according to standard procedures. RESULTS Blood samples from six patients with metastatic NSCLC were processed on the ISET device, which allows CTC enrichment by blood filtration through filters with calibrated pores (Vona et al, 2000; Paterlini-Brechot and Benali, 2007). Triple fluorescent labelling with anti-vimentin, anti-pan-keratin antibodies and SYTOX orange for nuclear staining was performed to detect CTCs using confocal microscopy. Control experiments were performed in parallel using 25 cells of SKBR3 (pan-keratin positive), MDA-MB-435S (vimentin positive) and A549 (pan-keratin and vimentin positive) cell lines spiked in blood from healthy donors (Table 1). Blood samples from six healthy donors were also processed by ISET and labelled identically. Isolated and/or clusters of immunostained CTCs were morphocytologically identified by an experienced cytopathologist (PV) using bright field images (Figure 1A and F). A strong co-expression of vimentin and pan-keratin antigens (Figure 1B–E and G–J) was observed in almost all CTCs from the six NSCLC patients. Counts of dual CTCs co-expressing pan-keratin and vimentin, of only vimentin positive and only pan-keratin positive CTCs in the six NSCLC patients are presented in Table 1.

Read the complete text